Novo Nordisk (NVO)
(Real Time Quote from BATS)
$132.88 USD
+1.34 (1.02%)
Updated Jul 22, 2024 03:18 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
NVO 132.88 +1.34(1.02%)
Will NVO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
Other News for NVO
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Novo Nordisk Advances Share Buyback Program
Hims & Hers appoints former Novo Nordisk president to board
Healthcare 2024 Second Half Outlook
7 Sorry Biotech Stocks Set to Make Investors Sad